{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:17:13Z","timestamp":1774343833921,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,23]]},"DOI":"10.7759\/cureus.105738","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:45:51Z","timestamp":1774331151000},"source":"Crossref","is-referenced-by-count":0,"title":["Adverse and Serious Adverse Events Associated With Tocilizumab in COVID-19 Pneumonia and With Cyclosporin, Pazopanib, and Insulin Glargine in Other Diseases: A Single-Center Cross-Sectional Study From a Tertiary Care Center in Bangladesh"],"prefix":"10.7759","author":[{"given":"Kawser","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsalan","family":"Bangash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaseen","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faaraan","family":"Bangash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Reza","family":"Suny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A B M","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu B","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021, 19:141-54. 10.1038\/s41579-020-00459-7","journal-title":"Nat Rev Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang C","year":"2020","unstructured":"Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020, 55:105954. 10.1016\/j.ijantimicag.2020.105954","journal-title":"Int J Antimicrob Agents"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X2024e13392","article-title":"A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database","volume":"57","author":"Cui S","year":"2024","unstructured":"Cui S, Li L, Liu W, Zhao B, Zhong X. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database. Braz J Med Biol Res. 2024, 57:e13392. 10.1590\/1414-431X2024e13392","journal-title":"Braz J Med Biol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29383","article-title":"Current status of adverse event profile of cyclosporine in kidney, stem cell, and heart transplantations using the Japanese pharmacovigilance database","volume":"14","author":"Niinomi I","year":"2022","unstructured":"Niinomi I, Oyama S, Inada A, et al.. Current status of adverse event profile of cyclosporine in kidney, stem cell, and heart transplantations using the Japanese pharmacovigilance database. Cureus. 2022, 14:e29383. 10.7759\/cureus.29383","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07154-z","article-title":"Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK","volume":"20","author":"Hawkins R","year":"2020","unstructured":"Hawkins R, Fife K, Hurst M, et al.. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC Cancer. 2020, 20:670. 10.1186\/s12885-020-07154-z","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1563238","article-title":"Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database","volume":"16","author":"Wang T","year":"2025","unstructured":"Wang T, He G, Xiong W, Huang J. Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database. Front Pharmacol. 2025, 16:1563238. 10.3389\/fphar.2025.1563238","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2239","article-title":"Tocilizumab in COVID-19 pneumonia: practical proposals based on a narrative review of randomised trials","volume":"32","author":"Klopfenstein T","year":"2022","unstructured":"Klopfenstein T, Gendrin V, Kadiane-Oussou NJ, Conrozier T, Zayet S. Tocilizumab in COVID-19 pneumonia: practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2022, 32:e2239. 10.1002\/rmv.2239","journal-title":"Rev Med Virol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2059405","article-title":"Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis","volume":"11","author":"Yu SY","year":"2022","unstructured":"Yu SY, Koh DH, Choi M, Ryoo S, Huh K, Yeom JS, Yoon YK. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerg Microbes Infect. 2022, 11:1154-65. 10.1080\/22221751.2022.2059405","journal-title":"Emerg Microbes Infect"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","unstructured":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY). a randomised, controlled, open-label, platform trial. Lancet. 2021, 397:1637-45. 10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1946513","article-title":"Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database","volume":"20","author":"Charan J","year":"2021","unstructured":"Charan J, Dutta S, Kaur R, et al.. Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Expert Opin Drug Saf. 2021, 20:1125-36. 10.1080\/14740338.2021.1946513","journal-title":"Expert Opin Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70026","article-title":"Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia","volume":"8","author":"Larue M","year":"2024","unstructured":"Larue M, Labopin M, Schroeder T, et al.. Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia. Hemasphere. 2024, 8:e70026. 10.1002\/hem3.70026","journal-title":"Hemasphere"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S323499","article-title":"Real-world outcome and prognostic factors of pazopanib in advanced soft tissue sarcoma","volume":"13","author":"Alshamsan B","year":"2021","unstructured":"Alshamsan B, Badran A, Alshibany A, Maraiki F, Elshenawy MA, Elhassan T, Atallah JP. Real-world outcome and prognostic factors of pazopanib in advanced soft tissue sarcoma. Cancer Manag Res. 2021, 13:6755-66. 10.2147\/CMAR.S323499","journal-title":"Cancer Manag Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv184","article-title":"A randomized, double-blind, placebo-controlled, phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup","volume":"46","author":"Kawai A","year":"2016","unstructured":"Kawai A, Araki N, Hiraga H, et al.. A randomized, double-blind, placebo-controlled, phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn J Clin Oncol. 2016, 46:248-53. 10.1093\/jjco\/hyv184","journal-title":"Jpn J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0547-5","article-title":"A review of the safety and adverse event profile of the fixed-ratio combination of insulin glargine and lixisenatide","volume":"10","author":"Frias JP","year":"2019","unstructured":"Frias JP, Dex T, Roberts M, Kaplan A. A review of the safety and adverse event profile of the fixed-ratio combination of insulin glargine and lixisenatide. Diabetes Ther. 2019, 10:21-33. 10.1007\/s13300-018-0547-5","journal-title":"Diabetes Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/453728-adverse-and-serious-adverse-events-associated-with-tocilizumab-in-covid-19-pneumonia-and-with-cyclosporin-pazopanib-and-insulin-glargine-in-other-diseases-a-single-center-cross-sectional-study-from-a-tertiary-care-center-in-bangladesh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:45:51Z","timestamp":1774331151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/453728-adverse-and-serious-adverse-events-associated-with-tocilizumab-in-covid-19-pneumonia-and-with-cyclosporin-pazopanib-and-insulin-glargine-in-other-diseases-a-single-center-cross-sectional-study-from-a-tertiary-care-center-in-bangladesh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.105738","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}